Why It Matters
Changes to the 340B rebate model can significantly impact the financial health of essential hospitals and clinics, affecting their ability to serve low-income and uninsured patients. It also has implications for drug manufacturers and the overall healthcare supply chain.
Key Intelligence
- ■The Health Resources and Services Administration (HRSA) has unveiled a revised 340B rebate model.
- ■This new model is scheduled to be implemented starting in 2027.
- ■The 340B program requires pharmaceutical manufacturers to provide outpatient drugs at discounted prices to eligible healthcare organizations.